Nu Skin Enterprises. with ticker code (NUS) now have 4 analysts in total covering the stock. The consensus rating is pointing to ‘Hold’. The target price High/Low ranges between 43 and 38 and has a mean target at $40.25. Now with the previous closing price of $40.86 this would imply there is a potential downside of -1.5%. The 50 day MA is $40.66 and the 200 moving average now moves to $40.52. The market capitalization for the company is $2,054m. Find out more information at: https://www.nuskin.com
The potential market cap would be $2,023m based on the market consensus.
Nu Skin Enterprises., together with its subsidiaries, develops and distributes various beauty and wellness products worldwide. It offers skin care devices, cosmetics, and other personal care productsluding ageLOC LumiSpa and ageLOC LumiSpa iO, ageLOC Body Spa; and nutricentials skin care products. The company also provides wellness products, such as ageLOC Meta, LifePak nutritional supplements, ageLOC TR90 weight management system, and Beauty Focus Collagen+. In addition, it is involved in the research and product development of skin care products and nutritional supplements. The company sells its products under the Nu Skin, Pharmanex, and ageLOC brands through retail stores, website, digital platforms, and independent direct sellers and marketers, as well as a service center. Nu Skin Enterprises. was founded in 1984 and is headquartered in Provo, Utah.
The company has a dividend yield of 3.82% with the ex dividend date set at 24-2-2023 (DMY).
Other points of data to note are a P/E ratio of 19.88, revenue per share of 44.51 and a 5.34% return on assets.
